T-cell receptor recognizing influenza hemagglutinin peptide-MHC class II complex (HA-specific TCR (MHC II))

T-cell receptors (TCRs) recognizing influenza hemagglutinin (HA) peptides presented on MHC class II molecules are critical components of the adaptive immune system's response to influenza virus infection [1]. These receptors are primarily expressed on CD4+ T cells and are responsible for identifying viral antigens processed and displayed by professional antigen-presenting cells like dendritic cells and B cells [2]. One of the most well-studied epitopes is the HA306-318 peptide, which is frequently presented by HLA-DR molecules [3]. Upon recognition of the HA-MHC II complex, the TCR initiates signaling that leads to T-cell proliferation and the secretion of cytokines such as IL-2 and IFN-gamma [4]. This process is essential for providing help to B cells for high-affinity antibody production and for the recruitment of other immune effectors [5]. In clinical research, these TCRs are used as models to study immunological memory, vaccine efficacy, and the potential for TCR-engineered cell therapies [6]. Understanding the specificity and cross-reactivity of these receptors is also vital for investigating molecular mimicry, where viral-specific T cells might inadvertently target host tissues [7].

Other names

Influenza hemagglutinin-specific T-cell receptorHA-reactive TCRCD4+ T-cell receptor for influenza HAHA306-318 specific TCRInfluenza HA-specific CD4+ T-cell receptor

The T-cell receptor (TCR) recognizes a specific influenza hemagglutinin (HA) peptide fragment (e.g., HA306-318) bound to a Major Histocompatibility Complex (MHC) class II molecule (e.g., HLA-DR4) [1]. This binding event triggers a signal transduction cascade through the CD3 complex, leading to the activation of CD4+ T-helper cells [2]. Activated cells then orchestrate the immune response by secreting cytokines and assisting B-cell antibody production [3]. Drugs like vaccines provide the antigen to activate these receptors, while immunosuppressants like cyclosporine inhibit the downstream signaling pathways [4].